UK: To Sleep: Perchance To Snore

Last Updated: 22 August 2002
Article by Stephen James

From the summer of 1996 to the spring of 1998, the US corporation Medgen Inc. developed a natural health care product for the alleviation or prevention of snoring. The spray product’s efficiency was claimed to lie in the fact that, when sprayed into the mouth, it coated the soft tissues at the back of the throat, the vibration of these tissues apparently being the usual cause of snoring.

A name for this product, Snorenz, was coined by Medgen during the early part of 1997 and they filed a US trade mark application for the mark in May of that year. The product was sold in the US on a small scale during its development, but its major trade launch took place at a trade fair held in California in March 1998.

At that trade fair was a representative of the UK company Passion for Life Products (PFL), who specialise in the sale of natural health products. Business contacts were made between Medgen and PFL and these developed into more serious negotiations aimed at the sale of Medgen’s product in the UK. On 20th March 1998, PFL wrote to Medgen saying that they had done some initial market research and, as a result, believed that they could sell Snorenz successfully in the UK. In that letter, PFL said "We have decided that we would rather import the product under your (that is, Medgen’s) brand". However, Medgen, at this stage at least, made it clear to PFL that they were not concerned which trade mark was used to market the anti-snoring product in the UK. As a result of these negotiations, PFL was appointed Medgen’s exclusive UK distributor until the end of 1998. The precise terms under which this exclusive distributorship was to operate were never expressed either in writing or in any other way.

In June 1998, PFL ordered about 4000 Snorenz bottles and these were promptly delivered. The product received by PFL in response to this order was identical to the product Medgen sold in the USA. Initially, PFL marketed the product by mail order rather than retail sales. Within a very short time, it was having an impact on the UK market.

On 2nd August 1998, PFL filed a Community trade mark application for Snorenz in Classes 5, 10 and 20. They followed this, on 15th August 1998, with a UK trade mark application for the mark in Class 5. Both applications were filed in the name of PFL. Medgen were not informed about either of these filings. During the prosecution of the UK application, an earlier UK registration for the trade mark Snoreeze was cited. PFL overcame this objection by purchasing the registration for Snoreeze.

At the same time as PFL were filing their CTM and UK trade mark applications, they also informed Medgen that, in order to continue selling the Snorenz spray in the UK, the product labelling would have to be redesigned to comply with European Union regulations. PFL also wanted to use this relabelling opportunity to create a new UK label for retail sales which would have a more "pharmaceutical" image and thereby be more attractive to potential consumers. Medgen had no objection to this proposal. PFL therefore went ahead and redesigned the label at their own expense. In early September 1998, they sent a sample label to Medgen for their approval. The new label bore the trade mark Snorenz but did not mention Medgen as the manufacturer of the product or any reference to Snorenz being a trade mark. Although Medgen did not initially express any concern about these omissions, at the beginning of October 1998 they allegedly wrote to PFL asking for the words "manufactured by Medgen Inc" to be added to the label and for ® to be added adjacent to Snorenz. This fax was never received by PFL. However, PFL were contacted by telephone by Medgen soon after to discuss these issues. PFL persuaded Medgen that their (PFL’s) name should appear on the new label because PFL would have to deal with any enquiries or complaints which arose in the UK. The new label (minus any reference to Medgen and ®) was again shown to Medgen at a meeting held between Medgen and PFL in the USA in November 1998.

From about October 1998 onwards, PFL sold Snorenz with the redesigned label both through retail and mail order outlets to the general public. They applied the new label to unlabelled bottles that they received from Medgen. Sales increased steadily until PFL’s UK sales amounted to 17% of total Snorenz spray sold around the world. Towards the end of 1998, the two parties began negotiating a new exclusive distributorship agreement to cover the whole of Europe. In a draft agreement, forwarded by PFL to Medgen, was a term which provided for PFL to own the goodwill in the mark Snorenz. Although a little slow to understand the impact of this clause, Medgen eventually, in April 1999, objected to it. They also (at last) conducted a trade mark search of the CTM and UK Trade Mark Registers and noted PFL’s trade mark application. In response, on 5th May 1999, Medgen filed their own UK trade mark application for Snorenz (stylised) in Class 5.

The parties now took up opposite positions. Medgen wanted the return of the Snorenz trade mark in the European Union, including the UK, in return for giving PFL a European wide exclusive distributorship. PFL did not want to give up their UK and CTM trade mark rights. Not surprisingly, relations between the two companies became soured and, in August 1999, Medgen opposed PFL’s UK trade mark application on the ground that it had been filed in bad faith. In spite of this, commercial dealings between originator and distributor limped on, with Medgen supplying PFL with unlabelled bottles of spray until November 1999.

At this point, it became clear to PFL that the continued supply of spray from Medgen could no longer be guaranteed. It therefore set about arranging for a similar product to be made by another manufacturer and having the product tested. Again, PFL kept their plans secret. PFL was ready to launch their new anti-snoring product in May 2000 which they did under the new name Snoreeze. It will be recalled that PFL had acquired the UK trade mark registration for Snoreeze during the prosecution of their UK trade mark application for Snorenz. The packaging of PFL’s Snoreeze spray was, for all practical purposes, identical to their (PFL’s) earlier Snorenz product. During the launch of their new product, PFL claimed that Snoreeze had won an award in 1999. This was untrue. The award had been won by Snorenz.

Soon after the launch of Snoreeze, Medgen brought proceedings for passing off against PFL in the English High Court. They claimed that

  • They (Medgen) owned the UK goodwill in the trade mark Snorenz and its packaging, and
  • PFL had made misrepresentations about the product Snoreeze, so as to connect it with the product Snorenz in the minds of the UK purchasing public.

In relation to the passing off case brought before the Court (Mr Garnett Q.C.), it was ruled that, PFL, rather than Medgen, were the exclusive owner of the UK goodwill in the trade mark Snorenz and the product’s packaging and that therefore Medgen’s action failed. The Court commented as follows:

  • Goodwill is local in character. Goodwill in relation to a business carried on in the UK is attached to that business. It is nevertheless legally and factually possible for a business based overseas to acquire goodwill in this country by the supply of its products through an agent, licensee or distributor. Whether it does so or not depends on the facts of the case, in particular, what was done and by whom. With whom do the relevant members of the public associate the name and get-up? Are they concerned with the quality and price of the product or the original source of the product?
  • Given that there is no rule of law or presumption of fact which says that the goodwill generated by the trading activities of a wholly owned subsidiary belongs to the parent or is the subject of any kind of licence, the same must apply with just as much force to the trading activities of an independent exclusive distributor.
  • On the evidence, it was clear that the wholesale or retail trade only knew PFL as the source of the product. It was to PFL that such traders would go for the product. In the event of any defect or problem, it was to PFL rather than to Medgen that a wholesaler or retailer would turn.
  • There was no evidence that UK retail traders either knew that Medgen had developed the product or that they (Medgen) were responsible for its manufacture. Further, such retail traders did not care about the development and/or manufacture of the spray. The above comments applied with even more force to members of the purchasing public.
  • The UK purchasing public was influenced by advertising or product references which carried PFL’s name. If they made successive purchases, they would do so either by contacting PFL or by identifying Snorenz and its local UK packaging in a shop. If the product failed to live up to the expectations they would have blamed PFL.

Turning to Medgen’s opposition, in the UK Trade Mark Office, to PFL’s UK trade mark application for Snorenz dated 15th August 1998, the Hearing Officer found that the opponent’s bad faith objection (under Section 3(6) of the 1994 Trade Marks Act) failed. He made the following comments on the case before him and bad faith actions in general,

  • Quoting from Gromax Plasticulture v Dow & Low Nonwovens (1999 RPC 367), "…bad faith…plainly includes dishonesty, and…also some dealings which fall short of the standards of acceptable commercial behaviour as observed by reasonable and experienced men in the particular area being examined".
  • Quoting from Eicher v Velocette Motorcycle (unreported, Appointed Person), "An allegation that a trade mark has been applied for in bad faith is a serious allegation. It is an allegation of a form of commercial fraud. A plea of fraud should not be lightly made…It should not be made unless it can be fully and properly pleaded and should not be upheld unless it is distinctly proved and this will rarely be possible by a process of inference".
  • The relevant date in the opposition proceedings was the date of application (15th August 1998). In relation to Section 3(6) the applicant’s motives or intentions must be construed at the time the application was made.
  • A vague suspicion that a foreign proprietor may wish to extend its trade under a mark to the UK is insufficient to found an objection under Section 3(6). However, if an applicant for registration of a trade mark has reasonable grounds to believe that a foreign user of the trade mark has plans to extend its trade under the trade mark into the UK, the application may be deemed to have been filed in bad faith.
  • PFL had suggested that the product be sold under the trade mark Snorenz in the UK and were told by Medgen, prior to any UK sales taking place, that it did not matter to Medgen under what name the product was sold in the UK. Following receipt of this information PFL could reasonably infer that Medgen was merely keen to sell the product in the UK and had no particular concerns to use the Snorenz mark itself in the UK.


This is a salutary trade mark tale. It seems clear that, as a result of Medgen’s acquiescence to the sale of Snorenz under PFL’s terms from about October 1998 onwards, the UK rights to the mark drifted away from Medgen to PFL. The need to exercise control over a licensee, subsidiary and/or distributor and, in particular, their use of a prized asset such as a trade mark has never been better illustrated.

Having said that, it is also clear to the writer that the opposition to PFL’s UK trade mark application was wrongly decided. This is because the matter must be viewed at the UK application date (15th August 1998) rather than 12-18 months later. What was the position at 15th August 1998? First, PFL were Medgen’s exclusive UK distributor. Second, in a letter dated 20th March 1998, PFL wrote to Medgen as follows "We have decided that we would rather import the product under your brand" (emphasis added). Third, all of the Snorenz product sold in the UK up to 15th August 1998 was the spray with the US label and packaging. Fourth, PFL filed their UK (and CTM) application in secret, suggesting that they knew that their actions were, at the very least, not in the spirit of their commercial relationship with Medgen. If this sort of pre-emption by a distributor selling the original (US) product in the UK does not amount to bad faith, then this ground of opposition is virtually worthless.

The authorities (both the UK Trade Mark Office and the Courts) should also lighten up in relation to actions brought under the bad faith banner. Bad faith should not automatically be equated with fraud. It can also be a sharp commercial practice that simply falls on the wrong side of the line. Companies (and individuals) will always try to optimise their own position. The vast majority try not to do this dishonestly or fraudulently. However, many will test the limits of the law, including trade mark law, to see whether they can maximise their commercial advantage. It is submitted that this is simply what PFL did in this case. They did not act fraudulently but they did, in the writer’s view, act in a way that fell short of acceptable commercial behaviour. As a result, the Section 3(6) opposition brought against their UK trade mark application for Snorenz should have been successful.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.